The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Xuan Huang
No relevant relationships to disclose
Yangmin M. Ning
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
Paul Gustav Kluetz
No relevant relationships to disclose
David Adelberg
No relevant relationships to disclose
Marcia Mulquin
No relevant relationships to disclose
Ravi A. Madan
No relevant relationships to disclose
Carol Bassim
No relevant relationships to disclose
William D. Figg
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose